This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Enteral Glutamine Supplementation for the Patient With Major Torso Trauma

This study has been terminated.
National Institutes of Health (NIH)
Information provided by:
The University of Texas Health Science Center, Houston Identifier:
First received: September 12, 2005
Last updated: April 22, 2010
Last verified: December 2007
Glutamine is considered a conditionally essential amino acid during critical illness. After severe trauma, glutamine supplementation into the gastrointestinal tract may help maintain bowel function. We hypothesize that for the major torso trauma patient, high dose glutamine given enterally during resuscitation from shock and continued during enteral nutrition support is absorbed, available systemically and preserves gut integrity.

Condition Intervention Phase
Trauma Critical Illness Shock Drug: Glutamine Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Enteral Glutamine Supplement to Enteral Nutrition Support of the Major Torso Trauma Patient: Proposal for a Prospective Randomized Clinical Trial

Resource links provided by NLM:

Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Gut function

Secondary Outcome Measures:
  • Systemic appearance of glutamine

Estimated Enrollment: 20
Study Start Date: June 2005
Estimated Study Completion Date: September 2006
Detailed Description:
In this prospective, randomized, controlled trial of patients with major torso trauma, high-dose enteral glutamine and enteral nutrition will be given to research subjects while controls will receive isocaloric, isonitrogenous enteral support. Enteral tolerance, bowel integrity and permeability will be evaluated. The systemic appearance of glutamine will be measured.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult trauma patients meeting criteria for shock resuscitation
  • Major torso trauma
  • Admission to the Shock/Trauma Intensive Care Unit

Exclusion Criteria:

  • Age <18 years
  • Pregnant
  • Expected survival < 24 hours
  • Bowel in discontinuity
  • Renal failure: baseline serum creatinine>3.0 and/or dialysis
  • Admission total bilirubin >10 mg/dl
  • History of cirrhosis or cirrhosis apparent on exploratory laparotomy
  • Asystole or CPR required
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00178581

United States, Texas
University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
National Institutes of Health (NIH)
Principal Investigator: Margaret M McQuiggan, MS, RD, CNSD University of Texas Medical School at Houston
  More Information

Publications: Identifier: NCT00178581     History of Changes
Other Study ID Numbers: HSC-MS-05-0144
M01RR002558 ( U.S. NIH Grant/Contract )
Study First Received: September 12, 2005
Last Updated: April 22, 2010

Keywords provided by The University of Texas Health Science Center, Houston:
Critical Illness
Enteral Nutrition

Additional relevant MeSH terms:
Wounds and Injuries
Critical Illness
Disease Attributes
Pathologic Processes processed this record on September 21, 2017